Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGY
Volume 43, Issue 8, Pages 869-880
Publisher
Wiley
Online
2016-02-15
DOI
10.1111/1346-8138.13258
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data
- (2015) M.K.A. Basra et al. DERMATOLOGY
- Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan
- (2015) Y. Ohara et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database
- (2015) K. Kubota et al. BMJ Open
- Psoriatic Nail Disease: Quality of Life and Treatment
- (2015) Aditya K. Gupta et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
- (2014) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Prevalence of TNF- Blocker Immunogenicity in Psoriatic Arthritis
- (2014) M. Zisapel et al. JOURNAL OF RHEUMATOLOGY
- Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
- (2014) Mark G. Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
- (2014) Yoshiya Tanaka et al. Modern Rheumatology
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Japanese guidance for use of biologics for psoriasis (the 2013 version)
- (2013) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Consensus Guidelines for the Management of Plaque Psoriasis
- (2012) Sylvia Hsu ARCHIVES OF DERMATOLOGY
- Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
- (2012) Georg Schett et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
- (2012) K.A. Papp et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Matching physicians’ treatment recommendations to patients’ treatment preferences is associated with improvement in treatment satisfaction
- (2012) N. Umar et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
- (2012) Kim Papp et al. LANCET
- Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008
- (2011) Hidetoshi TAKAHASHI et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
- (2011) Atsuyuki IGARASHI et al. JOURNAL OF DERMATOLOGY
- Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents
- (2010) Wolfgang Weger BRITISH JOURNAL OF PHARMACOLOGY
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial
- (2010) Hideshi Torii et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
- (2010) Akihiko ASAHINA et al. JOURNAL OF DERMATOLOGY
- Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
- (2009) Arthur Kavanaugh et al. ARTHRITIS AND RHEUMATISM
- Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture
- (2009) Nozomu Toyama et al. JOURNAL OF MEDICAL VIROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search